The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Veru
Stock and Other Ownership Interests - Veru
VERU-111, an oral cytoskeleton disruptor, to treat men with metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent.
 
Mark Christopher Markowski
Honoraria - Clovis Oncology; Exelixis
 
Ronald F. Tutrone
Employment - Chesapeake Urology
Stock and Other Ownership Interests - Myovant Sciences; Novartis; Nymox; Veru
Consulting or Advisory Role - Exosome Diagnostics; Myovant Sciences
Speakers' Bureau - Exosome Diagnostics; Medivation/Astellas; Pfizer
Research Funding - Advantagene (Inst); Advaxis (Inst); Bayer (Inst); Exosome Diagnostics (Inst); Genomic Health (Inst); Janssen Oncology (Inst); MDxHealth (Inst); Medivation/Astellas (Inst); Merck (Inst); Neotract (Inst); Nymox (Inst); OncoCellMDx (Inst); OncoCellMDx (Inst)
 
Mario A. Eisenberger
Leadership - Veru
Stock and Other Ownership Interests - Veru
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Seagen
Travel, Accommodations, Expenses - Veru
 
Christopher Michael Pieczonka
Employment - Associated Medical Professionals of New York
Leadership - Associated Medical Professionals of New York
Stock and Other Ownership Interests - US Urology Partners
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Janssen; Merck; Myovant Sciences; Pfizer/Astellas; Sun Pharma; Tolmar
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Janssen Oncology; Merck; Pfizer/Astellas; Sun Pharma; Sun Pharma; Tolmar
Speakers' Bureau - Astellas Pharma; Bayer; Dendreon; Janssen Oncology; Merck; Myovant Sciences; Pfizer; Sun Pharma; Tolmar
Research Funding - Advantagene; Astellas Pharma; AstraZeneca; Bayer; Dendreon; Innocrin Pharma; Janssen Oncology; Merck; Pfizer
 
Robert H. Getzenberg
Employment - Veru; Veru
Leadership - Veru
Stock and Other Ownership Interests - Veru; Veru
Consulting or Advisory Role - Veru
 
Domingo Rodriguez
No Relationships to Disclose
 
K. Gary Barnette
Employment - Veru
Leadership - Veru
Stock and Other Ownership Interests - Veru
 
Mitchell S. Steiner
Employment - Veru
Leadership - Veru
Stock and Other Ownership Interests - Veru
Patents, Royalties, Other Intellectual Property - Veru
 
Daniel Saltzstein
Research Funding - Veru (Inst)
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Lilly; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi